Breakthrough therapy program continues to produce a steady flow of submissions. Products recently leaving the clinic for the FDA review arena include Vertex Pharmaceuticals Inc.'s latest cystic fibrosis therapy, a rare disease therapy from Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co. Ltd., and Roche's antibody for hemophilia A patients with inhibitors.
Kyowa Hakko Kirin had a particularly good week. The Japan-based company also announced a breakthrough therapy designation (BTD) for another...







